Metabolic & GLP
Metabolic Regulation Studies
Size
Quantity
Ships from the United States with tracking · free shipping over $200
Certificates of analysis
Each certificate covers one production run, and reports on that batch alone. Open any of them to read the laboratory report exactly as the third-party lab issued it.
Authenticity
Scan the code on the label to pull up every published certificate for that compound — the same reports the third-party laboratory issued, batch by batch. Traceable from the laboratory that tested it to your bench.
Verify a batch →Independently tested
Purity is quantified by reverse-phase HPLC and identity confirmed by mass spectrometry, by an outside laboratory rather than in-house.
A certificate for your lot
The report that ships with your order describes the batch you received — not the product line, and not a representative sample.
COA-backed replacement
If material does not match the certificate issued for its lot, we replace it or refund it. Send us the lot number and we will trace it.
Tracked dispatch
Tracking is issued when the label is created, so the shipment is traceable from the moment it leaves us.
About this compound
GLP-3 RT is the research designation for LY3437943, a triple agonist engaging the GLP-1, GIP and glucagon receptors simultaneously. Single- and dual-agonist compounds are far better characterized; the research question specific to triple agonism is what the glucagon-receptor component contributes to metabolic endpoints on top of the other two.
How it works
The pathways GLP-3 RT acts on, and what each one does. Signalling described from preclinical models.
Incretin Receptor Agonism
The GLP-1 receptor component is the best-characterized of the three, and the one shared with every single- and dual-agonist compound in this class. It is the reference arm against which the additional receptor activity is measured.
Gastric Inhibitory Signalling
The GIP receptor arm is the addition that distinguishes dual agonists from single. Published work examines whether GIP agonism, antagonism or neither best complements GLP-1 activity — a question the literature has not settled.
Glucagon Receptor Agonism
Glucagon receptor activity is what makes this compound a triple rather than dual agonist, and it is the least characterized of the three. Interest centers on hepatic energy expenditure — the endpoint the other two arms do not address.
Uses & applications
The main areas under study, and the study-reported figures behind them.
Phase 2 work reported dose-dependent weight change over 48 weeks, with the highest dose arm producing the largest reported effect in this compound class to date.
Jastreboff et al. 2023
Examined in type 2 diabetes models against dual-agonist and placebo comparators, with HbA1c as the primary endpoint.
Rosenstock et al. 2023
The glucagon arm is studied for whether it raises energy expenditure rather than only reducing intake — the mechanistic question specific to triple agonism.
Coskun et al. 2022
Liver fat fraction has been measured as a secondary endpoint, on the basis that glucagon receptor activity acts directly on hepatocytes.
Sanyal et al. 2024
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Molecular structure
The verified reference values for this compound.
No 3D structure published
This compound is a long, flexible chain. Any single three-dimensional arrangement would be one of an enormous number it can adopt, so we do not show one. The sequence and the reference values beside this are the reliable description.
Third-party verified
Every batch of GLP-3 RT is sent to an accredited independent laboratory before it ships. Here is what we screen for.
Quantifies purity and reports it on the lot certificate
Verifies the exact molecular identity
Lead, arsenic, cadmium & mercury
Bacterial endotoxin levels
No microbial contamination
Actual peptide mass per vial verified
FAQ
GLP-3 RT is the research designation for LY3437943, a triple agonist engaging the GLP-1, GIP and glucagon receptors simultaneously. Single- and dual-agonist compounds are far better characterized; the research question specific to triple agonism is what the glucagon-receptor component contributes to metabolic endpoints on top of the other two.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. GLP-3 RT is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
For research use only
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
